Featured Articles

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and EMA. Nintedanib…
Read More...

Iktos announced a collaboration agreement with Merck KGaA, Darmstadt, Germany where Iktos generative modelling artificial intelligence (AI) technology will be used to facilitate the…
Read More...

Patients with HER2-positive breast cancer face something of a predicament: The most effective drug to treat the cancer is also the most toxic. Trastuzumab, sold under the brand name…
Read More...

Roche announced that the European Commission has approved MabThera® (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare condition…
Read More...

Roche announced that the European Commission has approved Hemlibra (emicizumab) for routine prophylaxis of bleeding episodes in people with severe haemophilia A (congenital factor VIII…
Read More...

Seres Therapeutics announced a three-year research collaboration with AstraZeneca. The collaboration will focus on advancing mechanistic understanding of the microbiome in augmenting…
Read More...

Pfizer Inc. announced the United States (U.S.) Food and Drug Administration (FDA) has approved TRAZIMERA (trastuzumab-qyyp), a biosimilar to Herceptin (trastuzumab), for the treatment…
Read More...

Gilead Sciences, Inc. announced findings from two studies that support the further development of GS-6207, a novel, selective, first-in-class inhibitor of HIV-1 capsid function, for…
Read More...

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced positive results from the Phase III POLO trial. Results from…
Read More...

AbbVie and Voyager Therapeutics announced an exclusive, global strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed at pathological…
Read More...

Abbott and Novo Nordisk announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital…
Read More...

Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application for ESPEROCT for the treatment of adults and children with…
Read More...

Boehringer Ingelheim and Eli Lilly and Company announced CAROLINA (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) met its primary…
Read More...

Merck, known as MSD outside the United States and Canada, announced the presentation of interim data from the Phase 1b/2 KEYNOTE-365 umbrella trial investigating KEYTRUDA, Merck’s…
Read More...

Novartis announced that the US Food and Drug Administration (FDA) has approved Egaten (triclabendazole) for the treatment of fascioliasis in patients six years of age and older. This…
Read More...

AbbVie, Teneobio, Inc. and its affiliate TeneoOne, Inc. announced that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting…
Read More...

The Epilepsy Society and UCB, a global biopharmaceutical company headquartered in Belgium, with a significant UK R&D hub in Slough, UK, have announced an exciting new collaboration…
Read More...

GlaxoSmithKline plc and Merck KGaA, Darmstadt, Germany announced that they have entered into a global strategic alliance to jointly develop and commercialise M7824 (bintrafusp alfa).…
Read More...

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD)…
Read More...

BioNTech AG, a rapidly growing biotechnology company developing precise and individualized immunotherapies for the treatment of cancer and the prevention of infectious diseases, and MAB…
Read More...